Sunday, March 3, 2024

US, French firms start drug trial in severe coronavirus cases

French pharmaceutical giant Sanofi and American drugmaker Regeneron said on Monday they have started clinical trials for a new drug in patients hospitalised with severe coronavirus infections.

In a statement, they said phase 2 and 3 trials were underway for Kevzara, an immunosuppressor.

Regeneron will begin trial in the United States, while Sanofi plans trials initially in Italy, particularly hard hit by the novel coronavirus pandemic.

Advertisement

Kevzara, the brand name for sarilumab, an antibody that blocks the ability of some viruses to latch on to humane immune cells, has been in development since 2017.

Specifically, it inhibits the immune receptor that plays a key role in lung inflammation, something severe coronavirus patients suffer from.

Around 400 patients will take part in the studies, which will evaluate the effect of Kevzara on fever and oxygenation levels of patients.

Advertisement

It will also look at how the drug works over the long term in reducing mortality rates, and potentially how it can reduce the need for respiratory apparatus in hospitals.

The number of novel coronavirus cases globally stood at 168,250 with 6,501 deaths, across 142 countries and territories at 0900 GMT Monday, according to an AFP tally based on official sources.

Signaturetv.org/AFP/OA

Signature TV
Signature TVhttps://signaturetv.isitedigitals.com
Signature TV is a multi-media company, owners and operators of signaturetv.org and producers of The Signature Show on AIT and Corruption Tori. Our programmes are broadcast on the AIT Network and on Seven NTA stations across the country. We are content providers for a number of television networks and some State TV stations, with a respected 24/7, high online and offline followership. We are also Communications/Media Consultants to MacArthur Foundation, Ford Foundation and OSIWA.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!

Latest Articles